The aim of this study is to evaluate the expression of Tim-3 adapter molecules, Fyn and Bat3, in CLL patients which could help identifying immune regulation mechanisms in this malignancy and introducing novel immunotherapy targets to enhance the response of T-cells in these patients. Here, HAVCR2 is linked to B-cell chronic lymphocytic leukemia.